Skip to main content

Table 3 Analysis of anthracycline sub-groups (AC60, FEC75 and FAC50) homogeneity (test Pearson Khi2)

From: Concurrent chemoradiotherapy in adjuvant treatment of breast cancer

Patients characteristics Group FEC75 [n = 23] No (%) Group FAC50 [n = 20] No (%) Group AC60 [n = 57] No (%) p value
Age
   <40 8 (34.8%) 7 (35%) 14 (24.6%) 0.53
   ≥40 15 (65.2%) 13 (65%) 43 (75.4%)  
Menopausal status
   No 20 (90.9%) 14 (77.8%) 35 (66%) 0.075
   Yes 2 (9.1%) 4 (22.2%) 18 (34%)  
Side
   Right 14 (60.9%) 7 (35%) 24 (42.1%) 0.188
   Left 9 (39.1%) 13 (65%) 33 (57.9%)  
Surgery
   Mastectomy 5 (21.7%) 5 (25%) 8 (14%) 0.457
   Conservative 18 (78.3%) 15 (75%) 49 (86%)  
Histology
   CCI 20 (95.2%) 19 (95%) 52 (94.5%) 0.992
   CLI 1 (4.8%) 1 (5%) 3 (5.5%)  
SBR
   I 0 1 (5%) 4 (7.1%) 0.31
   II 14 (70%) 10 (50%) 39 (69.6%)  
   III 6 (30%) 9 (45%) 13 (23.2%)  
Hormonal receptors
ER
   Positive 18 (81.8%) 11 (55%) 42 (76.4%) 0.106
   Negative 4 (18.2%) 9 (45%) 13 (23.6%)  
PR
   Positive 17 (77.3%) 7 (35%) 31 (57.4%) 0.022
   Negative 5 (22.7%) 13 (65%) 23 (42.6%)  
Tumour
   pT1 6 (26.1%) 1 (5%) 9 (16.1%) 0.514
   pT2 10 (43.5%) 13 (65%) 32 (57.1%)  
   pT3 7 (30.4%) 5 (25%) 13 (23.2%)  
   pT4 0 1 (5%) 2 (3.6%)  
pN, axillary
   pN0 6 (26.1%) 3 (15%) 9 (15.8%) 0.807
   pN1 4 (17.4%) 4 (20%) 15 (26.3%)  
   pN2 7 (30.4%) 5 (25%) 18 (31.6%%)  
   pN3 6 (26.1%) 8 (40%) 15 (26.3%%)  
  1. FEC75 = 5-fluorouracile 500 mg/m2, epirubicin 75 mg/m2, and cyclophosphamide 500 mg/m2; FAC50 = 5-fluorouracile 500 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2; AC60 = doxorubicin 60 mg and cyclophosphamide 600 mg/m2 ; SBR = Scarf-Bloom-Richardson; DIC = ductal invasive carcinoma; LIC = lobular invasive carcinoma; ER = estrogen receptor; PR = progesterone receptor